Literature DB >> 9660070

The capsid protein of vesicular exanthema of swine virus serotype A48: relationship to the capsid protein of other animal caliciviruses.

J D Neill1, R F Meyer, B S Seal.   

Abstract

Vesicular exanthema of swine virus (VESV), the prototype calicivirus, is the etiologic agent of the porcine disease vesicular exanthema of swine (VES). VES is characterized by vesicle formation on the extremities, mouth and snout and causes abortions and stillbirths if infection occurs during pregnancy. VESV is considered an exotic agent in the US, following its eradication in 1956. The single capsid protein gene of VESV serotype A48 was cloned and sequenced. The capsid amino acid sequence was 69% similar to the San Miguel sea lion virus serotype 1 (SMSV 1) and 89% similar to the SMSV serotype 4 (SMSV 4) capsid proteins. The six functional regions (A-F) previously identified in SMSV 1, SMSV 4, feline calicivirus and rabbit hemorrhagic disease virus capsid proteins were present in VESV A48. Two sets of PCR primers were designed which directed amplification of the 5' end (A region) and the hypervariable (E region) sequences of the capsid protein precursor gene of these viruses, as well as seven additional SMSV serotypes. Alignment and phylogenetic analysis of the N-terminal sequences demonstrated the close relationship of these viruses. Alignment of the hypervariable region amino acid sequences of the ten viruses confirmed that a great variety of sequence exists in this region; however, a consensus sequence (NxT(N/H)F(K/R)GxYI(C/M)GxLx(T/R)) was derived which is also present in the feline calicivirus capsid protein. Comparison of the E region sequences provides further evidence that this area of animal calicivirus capsid protein may contain the major antigenic determinants.

Entities:  

Mesh:

Year:  1998        PMID: 9660070     DOI: 10.1016/s0168-1702(98)00013-6

Source DB:  PubMed          Journal:  Virus Res        ISSN: 0168-1702            Impact factor:   3.303


  8 in total

1.  Characterization of a Vesivirus Associated with an Outbreak of Acute Hemorrhagic Gastroenteritis in Domestic Dogs.

Authors:  Randall W Renshaw; Jennifer Griffing; Jaime Weisman; Lisa M Crofton; Melissa A Laverack; Robert P Poston; Gerald E Duhamel; Edward J Dubovi
Journal:  J Clin Microbiol       Date:  2018-04-25       Impact factor: 5.948

2.  Characterization of an enteropathogenic bovine calicivirus representing a potentially new calicivirus genus.

Authors:  J R Smiley; K O Chang; J Hayes; J Vinjé; L J Saif
Journal:  J Virol       Date:  2002-10       Impact factor: 5.103

3.  High genetic diversity of the immunodominant region of the feline calicivirus capsid gene in endemically infected cat colonies.

Authors:  Alan D Radford; Susan Dawson; Ruth Ryvar; Karen Coyne; Deborah R Johnson; Michael B Cox; Els F J Acke; Diane D Addie; Rosalind M Gaskell
Journal:  Virus Genes       Date:  2003-10       Impact factor: 2.332

4.  Molecular characterization of bovine enteric caliciviruses: a distinct third genogroup of noroviruses (Norwalk-like viruses) unlikely to be of risk to humans.

Authors:  S L Oliver; A M Dastjerdi; S Wong; L El-Attar; C Gallimore; D W G Brown; J Green; J C Bridger
Journal:  J Virol       Date:  2003-02       Impact factor: 5.103

Review 5.  Caliciviridae Other Than Noroviruses.

Authors:  Ulrich Desselberger
Journal:  Viruses       Date:  2019-03-21       Impact factor: 5.048

6.  Genomic characterization of the unclassified bovine enteric virus Newbury agent-1 (Newbury1) endorses a new genus in the family Caliciviridae.

Authors:  S L Oliver; E Asobayire; A M Dastjerdi; J C Bridger
Journal:  Virology       Date:  2006-03-30       Impact factor: 3.616

Review 7.  Antiviral strategies to control calicivirus infections.

Authors:  Jacques Rohayem; Mirko Bergmann; Julia Gebhardt; Ernest Gould; Paul Tucker; Andrea Mattevi; Torsten Unge; Rolf Hilgenfeld; Johan Neyts
Journal:  Antiviral Res       Date:  2010-05-21       Impact factor: 5.970

8.  Vesivirus viremia and seroprevalence in humans.

Authors:  Alvin W Smith; Patrick L Iversen; Douglas E Skilling; David A Stein; Karin Bok; David O Matson
Journal:  J Med Virol       Date:  2006-05       Impact factor: 2.327

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.